Followers | 1320 |
Posts | 26903 |
Boards Moderated | 6 |
Alias Born | 12/10/2012 |
Tuesday, April 13, 2021 7:22:49 AM
Definitely worth watching now.
GO $VLON
******************************************************
Vallon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is primarily focused on the development and commercialization of proprietary biopharmaceutical products. It is focused on developing prescription drugs for central nervous system (CNS) disorders. Its clinical-stage product is Abuse-Deterrent Amphetamine Immediate-Release (ADAIR), an abuse-deterrent oral formulation of immediate-release (short-acting) dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. It also intends to develop other abuse-deterrent products, including the development of an abuse deterrent formulation of Ritalin (ADMIR). ADAIR is being designed as a formulation that resists manipulation and preparation for snorting and provides meaningful barriers to injection. ADMIR is designed to have abuse deterrent properties that are similar to ADAIR.
Headquarters
Two Logan Square 100 N. 18Th Street, Suite 300
Philadelphia, PA
19103
Recent VLON News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/01/2024 01:13:53 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/28/2024 08:45:04 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/28/2024 08:42:12 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/02/2024 09:25:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 09:23:00 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 02/02/2024 09:21:50 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/02/2024 05:15:17 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/30/2024 01:13:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 01:12:42 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/19/2024 09:16:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:15:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 01:45:50 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 12/20/2023 10:12:21 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/15/2023 10:02:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 02:07:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/27/2023 01:38:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/24/2023 09:04:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/15/2023 01:07:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/01/2023 12:45:57 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 10/13/2023 08:40:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/25/2023 08:42:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/23/2023 01:07:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2023 08:06:20 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 12:08:45 PM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM